ArticleNature communications2024
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.Frontiers in immunology · 2025Pooled it
- D3S-001 in advanced solid tumors with KRASNature medicine · 2025Trial
- Monovalent Nondegrading Molecular Glues: An Updated Overview of Emerging Mechanisms and Therapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target.Current oncology (Toronto, Ont.) · 2026Review
- A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior.The Journal of biological chemistry · 2026Article
- A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.Cancer discovery · 2026Review
- Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer.Molecular cancer therapeutics · 2026Article
- MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis.Respiratory research · 2026Article
- KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.Molecular cancer · 2026Review
- Review
- Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026Review
- Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation.Cell communication and signaling : CCS · 2026Article
- UnlockingCurrent oncology (Toronto, Ont.) · 2026Review
- Induced proximity-based therapeutic modalities.Nature reviews. Drug discovery · 2026Review
- Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.Journal for immunotherapy of cancer · 2026Article
- The ERK MAPK pathway in mesenchymal glioblastoma: tumorigenesis, microenvironmental reprogramming, and the therapeutic promise of RAS(ON) multi-selective inhibition.Frontiers in molecular neuroscience · 2026Review
- Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers.Frontiers in immunology · 2026Review
- KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.Frontiers in oncology · 2026Review
- Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASBritish journal of cancer · 2026Article
- First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.Cancer biology & therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Marie-Julie Nokin *INSERM U1312, University of Bordeaux, IECB, Pessac, France.
Alessia Mira *Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Enrico PatruccoDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.ORCID 0000-0001-8060-5058
Biagio RicciutiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sophie CousinDepartment of Medical Oncology, Institut Bergonié, Bordeaux, France.
Isabelle SoubeyranDepartment of Biopathology, Institut Bergonié, Bordeaux, France.
Sonia San JoséINSERM U1312, University of Bordeaux, IECB, Pessac, France.
Serena PeironeDepartment of Biosciences, Università degli Studi di Milano, Via Celoria 26, Milan, Italy.ORCID 0000-0002-5195-7908
Livia CaizziItalian Institute for Genomic Medicine, c/o IRCCS, Str. Prov. le 142, km 3.95, Candiolo, Torino, Italy.
Sandra Vietti MichelinaDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Aurelien BourdonDepartment of Biopathology, Institut Bergonié, Bordeaux, France.
Xinan WangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Daniel Alvarez-VillanuevaChemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
María Martínez-IniestaChemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-6252-6671
August VidalChemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-5727-2099
Telmo RodriguesComparative Pathology Unit, Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain.
Carmen García-MacíasComparative Pathology Unit, Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain.ORCID 0000-0002-5929-4926
Mark M AwadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ernest NadalDepartment of Medical Oncology, Catalan Institute of Oncology (ICO); Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, Oncobell Program, IDIBELL, L'Hospitalet, Barcelona, Spain.ORCID 0000-0002-9674-5554
Alberto VillanuevaChemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-5164-0006
Antoine ItalianoDepartment of Medical Oncology, Institut Bergonié, Bordeaux, France. a.italiano@bordeaux.unicancer.fr.ORCID 0000-0002-8540-5351
Matteo CeredaDepartment of Biosciences, Università degli Studi di Milano, Via Celoria 26, Milan, Italy. matteo.cereda@iigm.it.ORCID 0000-0003-1799-5537
David SantamaríaINSERM U1312, University of Bordeaux, IECB, Pessac, France. d.santamaria@usal.es.ORCID 0000-0002-4711-3569
Chiara AmbrogioDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy. chiara.ambrogio@unito.it.ORCID 0000-0003-4122-701X
Funding
Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 2021 - ID. 25737EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101001288Fondazione Italiana per la Ricerca sul Cancro (Italian Foundation for Cancer Research) MFAG 2017 ID. 20566, BRIDGE 2023 - ID. 28739Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) EPAEC222641CICS, PRYGN222960SANTGeneralitat de Catalunya (Government of Catalonia) 2021SGR00184Giovanni Armenise-Harvard Foundation CDA-2019Institut National Du Cancer (French National Cancer Institute) INCA_13911Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI19/01320Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI21/00789, PI21/00789, FIS PI22-00548
Abstract
Selective KRAS
Indexed as
Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsProto-Oncogene Proteins p21(ras)AcetonitrilesAnimalsCell Line, TumorFemaleGuanosine TriphosphateHumansMiceMutationPiperazinesPyridinesPyrimidinesXenograft Model Antitumor AssaysAcetonitrilesadagrasibGuanosine TriphosphateKRAS protein, humanPiperazinesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.